VEGFA and neoplasm: The comparison was extended to monitoring during 3 weeks the effect of bevacizumab, an anti-angiogenic antibody raised against vascular endothelial growth factor (VEGF), on these two models, by measuring the tumour diameter and by performing PET imaging at three time points.